LIFECORE BIOMEDICAL, INC. Proceeds from Sale and Maturity of Marketable Securities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Proceeds from Sale and Maturity of Marketable Securities of $2.96 million for the 12-month period ending 2014-05-25, per its 10-K filed 2016-08-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2016-08-01
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2012-05-27 was $18.60M, a 154.55% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2012-02-26 was $9.10M.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2011-11-27 was $6.80M.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2011-08-28 was $14.18M, a 1.44% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for fiscal 2014 was $2.96M, a 13.24% decline from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for fiscal 2013 was $3.41M, a 87.68% decline from fiscal 2012.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for fiscal 2012 was $27.70M, a 1.51% increase from fiscal 2011.
- LIFECORE BIOMEDICAL, INC. proceeds from sale and maturity of marketable securities for fiscal 2011 was $27.29M, a 186.03% increase from fiscal 2010.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 6 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 9 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2014-05-25 | $2.96M 10-K · filed 2016-08-01 | $0.00 10-K · filed 2014-08-01 | |||||
| 2013-05-26 | $3.41M 10-K · filed 2015-07-31 | $0.00 10-K · filed 2013-08-07 | |||||
| 2012-05-27 | $18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $27.70M derived: sum of 2 quarters · filed 2013-08-07 | $34.50M derived: sum of 3 quarters · filed 2013-08-07 | $27.70M 10-K · filed 2013-08-07 | $27.74M 10-K · filed 2012-08-08 | ||
| 2012-02-26 | $9.10M 10-Q · filed 2013-04-04 | $15.90M derived: sum of 2 quarters · filed 2013-04-04 | $9.10M 10-Q · filed 2013-04-04 | $19.58M 10-Q · filed 2012-03-28 | $37.38M derived: sum of 4 quarters · filed 2013-04-04 | ||
| 2011-11-27 | $6.80M 10-Q · filed 2013-01-04 | $6.80M 10-Q · filed 2013-01-04 | $22.95M 10-Q · filed 2012-01-05 | $28.28M derived: sum of 3 quarters · filed 2013-01-04 | |||
| 2011-08-28 | $14.18M 10-Q · filed 2011-10-05 | $21.48M derived: sum of 2 quarters · filed 2012-08-08 | |||||
| 2011-05-29 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-08 | $27.29M 10-K · filed 2012-08-08 | |||||
| 2011-02-27 | $19.98M 10-Q · filed 2012-03-28 | ||||||
| 2010-11-28 | $22.61M 10-Q · filed 2012-01-05 | ||||||
| 2010-08-29 | $14.38M 10-Q · filed 2011-10-05 | ||||||
| 2010-05-30 | $9.54M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |